Innovation Kyoto 2021 Investment Limited Liability Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Ko Kusumi) as unlimited liability partner, has made an additional investment in Orizuru Therapeutics, Inc. (headquartered in Sakyo-ku, Kyoto; Kenji Nonaka, Representative Director) through a third-party allocation of new shares.

Overview of this investment
Orizuru is a biotech that develops regenerative medicine products and innovative iPS cell related technologies that utilize research results from Kyoto University.

We have raised a total of approximately 3.3 billion yen through a Series B round of third-party allotment of new shares. The total amount raised through third-party allotments, including this round, exceeds 9.5 billion yen, and including grants from the AMED (Japan Agency for Medical Research and Development) program, the total amount raised since the company's establishment exceeds 10 billion yen.

This financing will accelerate the clinical development and manufacturing of innovative regenerative medicine products using iPS cell-derived cardiomyocytes and iPS cell-derived pancreatic islet cells, which Orizuru is independently developing. In addition, ORIZUR will continue to support drug discovery research and develop the infrastructure for regenerative medicine research through the utilization of iPS cell-related technology, and will develop the social implementation of iPS cell technology.

Kyoto iCAP has made an additional investment of 500 million yen in hopes that Orizuru's regenerative medicine products and innovative iPS cell-related technologies will lead to the creation of groundbreaking regenerative medicine products. In addition to Kyoto iCAP, the private placement of approximately 3.3 billion yen in total by Orizuru was supported by JGCI (Tokyo, Japan), Takeda Pharmaceutical Company Limited (Osaka, Japan), Mitsubishi UFJ Bank Limited (Tokyo, Japan), SMBC Venture Capital (Tokyo, Japan), JDRF T 1D Fund, LLC (Boston, U.S.A.).

.

About Orizuru Therapeutics, Inc.
Established April 9, 2021
Business Description 1) Development of regenerative medical products using cell transplantation
　　　　　　　　2. support for drug discovery research and development of regenerative medicine research infrastructure utilizing iPS cell-related technologies
Head Office Address 36-1, Yoshida Honmachi, Sakyo-ku, Kyoto, Japan
Institute Location: Shonan Health Innovation Park, 2-26-1 Muraoka Higashi, Fujisawa-shi, Kanagawa, Japan
Representative Director Kenji Nonaka
HP URL                https://orizuru-therapeutics.com/

About the product under development.
OZTx-410 is an iPS cell-derived islet cell product produced by our proprietary method using low molecular weight compounds. Composed of safe and highly purified pancreatic endocrine cell aggregates, OZTx-410 is expected to exhibit physiological insulin secretory ability in response to glucose loading and hypoglycemia. We plan to initiate clinical trials to normalize blood glucose levels and improve the quality of life of patients with severe type 1 diabetes using our transplantation method that enables long-term viability of OZTx-410 and reproduction of pancreatic islet structure.

OZTx-556 is an iPS cell-derived cardiomyocyte product produced by our proprietary method using a low molecular weight compound. OZTx-556, a highly pure and safe cardiomyocyte product with high viability to the heart, is expected to replenish cardiomyocytes lost as the disease progresses and promote re-myocardialization. The company plans to initiate clinical trials with the aim of restoring cardiac function, improving physical function, and improving the life expectancy of patients with severe heart failure, which has been considered difficult to treat.

About Kyoto University Innovation Capital Co., Ltd.
As a wholly-owned subsidiary of Kyoto University, Kyoto iCAP invests in and provides other business support to companies that utilize research results generated at Kyoto University and other national universities. The firm currently operates the Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No. 1 Fund") (established in January 2016) with a total value of ¥16 billion and the KYOTO-iCAP No. 2 Fund (established in January 2021) with a total value of ¥18.1 billion. The KYOTO-iCAP 1 Fund has a maturity of up to 20 years, and the KYOTO-iCAP 2 Fund has a maturity of up to 17 years, making it possible to provide long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. The maximum maturity of the KYOTO-iCAP 2 Fund is 17 years. In addition, a portion of the KYOTO-iCAP No. 2 Fund will be invested in national university-launched ventures outside of Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1, Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
info@kyoto-icap.co.jp
TEL: 075-753-7588